LEXX vs. UNCY, CARA, XLO, APLM, PMN, IMRX, BOLT, RMTI, MRKR, and EYEN
Should you be buying Lexaria Bioscience stock or one of its competitors? The main competitors of Lexaria Bioscience include Unicycive Therapeutics (UNCY), Cara Therapeutics (CARA), Xilio Therapeutics (XLO), Apollomics (APLM), ProMIS Neurosciences (PMN), Immuneering (IMRX), Bolt Biotherapeutics (BOLT), Rockwell Medical (RMTI), Marker Therapeutics (MRKR), and Eyenovia (EYEN). These companies are all part of the "pharmaceutical preparations" industry.
Lexaria Bioscience (NASDAQ:LEXX) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, community ranking, dividends, institutional ownership, risk and earnings.
13.1% of Lexaria Bioscience shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 7.6% of Lexaria Bioscience shares are held by insiders. Comparatively, 42.0% of Unicycive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Unicycive Therapeutics received 16 more outperform votes than Lexaria Bioscience when rated by MarketBeat users. However, 100.00% of users gave Lexaria Bioscience an outperform vote while only 64.29% of users gave Unicycive Therapeutics an outperform vote.
Lexaria Bioscience has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 2.72, suggesting that its stock price is 172% more volatile than the S&P 500.
In the previous week, Lexaria Bioscience had 7 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 7 mentions for Lexaria Bioscience and 0 mentions for Unicycive Therapeutics. Lexaria Bioscience's average media sentiment score of 0.55 beat Unicycive Therapeutics' score of 0.00 indicating that Lexaria Bioscience is being referred to more favorably in the media.
Lexaria Bioscience presently has a consensus target price of $12.00, suggesting a potential upside of 238.98%. Unicycive Therapeutics has a consensus target price of $5.30, suggesting a potential upside of 369.03%. Given Unicycive Therapeutics' higher probable upside, analysts plainly believe Unicycive Therapeutics is more favorable than Lexaria Bioscience.
Unicycive Therapeutics' return on equity of 0.00% beat Lexaria Bioscience's return on equity.
Lexaria Bioscience has higher earnings, but lower revenue than Unicycive Therapeutics. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Unicycive Therapeutics beats Lexaria Bioscience on 10 of the 16 factors compared between the two stocks.
Get Lexaria Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for LEXX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LEXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lexaria Bioscience Competitors List
Related Companies and Tools
